stem-cells-istock-577639302_posteriori
posteriori / iStockphoto.com
16 February 2018Americas

Astellas Pharma expands portfolio by acquiring Universal Cells

Japan-based Astellas Pharma has acquired US-based Universal Cells in a move that will allow it to develop universal donor cell technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 October 2016   Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq.
Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.

More on this story

Americas
24 October 2016   Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq.
Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.

More on this story

Americas
24 October 2016   Japanese drug company Astellas has filed a complaint against Canada-based Apotex for allegedly infringing its patents centring on the drug Myrbetriq.
Asia-Pacific
15 August 2018   Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.